The company will be publishing more of the data. This is one that did not benefit from hundreds of millions of government funding of the trials.
-
-
-
Was there an efficacy trial, though? I can't find any. and the NPR story hints there is. If so, that's great! Trust is so crucial to vaccines. Yeah it's baffling if they did not get funding for trials. A lot more trials in the public-interest would be great. All for it.
- Show replies
New conversation -
-
-
It’s been a stunning PR coup, that’s for sure. Future documentary: “Making of a Hero: How to Save The World with No Data.”
-
Spiritual sequel to "The Inventor"
End of conversation
New conversation -
-
-
Wapo in December. https://archive.is/3GoF0 pic.twitter.com/xPuf29SKhU
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
there is no efficacy data, it's all serological correlates. The Indian FDA equivalent isn't asking for VE data, so the company didn't even bother. They just compared the antibody levels to AZ & another local vaccine...
-
If I am in an LMIC, I would rather have the Novavax w/ much superior VE data & potential efficacy against variants than this... but ymmv
End of conversation
New conversation -
-
-
Is it similar to Novavax ? U already know links given here https://www.scientificamerican.com/article/a-covid-vaccine-for-all/ … & those of Ggleschol (Corbevax, RBD219-N1C1, RBD 219-N1C1, RBD219-N1, with or without typographical spaces, not same result) (If u allow, reminder for those, like me, who want to follow subject)
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@PeterHotez any insight?Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@GKangInd — do you know?Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.